{
    "id": 2694,
    "fullName": "BCR - ABL1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "BCR-ABL1 (BCR-ABL) results from the fusion of BCR and ABL1, which leads to constitutive ABL1 kinase activity, activation of downstream signaling, and cell transformation (PMID: 22156549, PMID: 18827185). BCR-ABL1 frequently results from a translocation termed the Philadelphia chromosome, and is prevalent in chronic myeloid leukemia (PMID: 18827185, PMID: 21435002).",
            "references": [
                {
                    "id": 10244,
                    "pubMedId": 18827185,
                    "title": "Molecular biology of bcr-abl1-positive chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18827185"
                },
                {
                    "id": 10246,
                    "pubMedId": 21435002,
                    "title": "ABL1 fusion genes in hematological malignancies: a review.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21435002"
                },
                {
                    "id": 10245,
                    "pubMedId": 22156549,
                    "title": "Molecular pathways: BCR-ABL.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22156549"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 613,
        "geneSymbol": "BCR",
        "terms": [
            "BCR",
            "ALL",
            "BCR1",
            "CML",
            "D22S11",
            "D22S662",
            "PHL"
        ]
    },
    "variant": "BCR - ABL1",
    "createDate": "12/04/2014",
    "updateDate": "11/06/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 25,
                "geneSymbol": "ABL1",
                "terms": [
                    "ABL1",
                    "ABL",
                    "BCR-ABL",
                    "bcr/abl",
                    "c-ABL",
                    "c-ABL1",
                    "CHDSKM",
                    "JTK7",
                    "p150",
                    "v-abl"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 11537,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AIC-47 suppressed BCR-ABL1 transcription through down-regulation of Myc, resulted in cell death in chronic myeloid leukemia cell lines in culture (PMID: 25644089).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 6020,
                "therapyName": "AIC-47",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9605,
                    "pubMedId": 25644089,
                    "title": "Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25644089"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10727,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Gleevec (imatinib) and Serdemetan (JNJ-26854165) synergistically inhibited growth of chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 27999193).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 5602,
                "therapyName": "Imatinib + Serdemetan",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8788,
                    "pubMedId": 27999193,
                    "title": "The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27999193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6247,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, chronic myeloid leukemia patients with a low BCR-ABL1 transcript level (<10%) and fast BCR-ABL1 transcript elimination rate (halving time less than or equal to 17 days) responded best to tyrosine kinase inhibitor treatments including Gleevec (imatinib), Tasigna (nilotinib), or Sprycel (dasatinib) (PMID: 27131622).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5508,
                    "pubMedId": 27131622,
                    "title": "Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27131622"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12341,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (CA180-226) that supported FDA approval, treatment with Sprycel (dasatinib) in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase resulted in a major cytogenetic response in 98% (50/51) of patients, a complete cytogenetic response in 96% (46/51), and a major molecular response in 75% (38/51) (J Clin Oncol 35, no. 15_suppl (May 2017) 10511-10511; NCT00777036).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10336,
                    "pubMedId": null,
                    "title": "Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP)",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.10511"
                },
                {
                    "id": 15535,
                    "pubMedId": null,
                    "title": "Sprycel (dasatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18920,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is included in guidelines as a preferred regimen for patients with BCR-ABL1-positive chronic myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8434,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Sprycel (dasatinib) and Tasigna (nilotinib) resulted in comparable clinical outcome in propensity score-matched chronic phase chronic myeloid leukemia patients (PMID: 27509035).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6656,
                    "pubMedId": 27509035,
                    "title": "A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27509035"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2101,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (DASISION) that supported FDA approval, Sprycel (dasatinib), as compared to Gleevec (imatinib), resulted in a significantly greater complete cytogenetic response (86% vs 82%) and major molecular response (64% vs 46%) in newly diagnosed patients with Philadelphia chromosome positive chronic myeloid leukemia (PMID: 22160483; NCT00481247).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2620,
                    "pubMedId": 22160483,
                    "title": "Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22160483"
                },
                {
                    "id": 15535,
                    "pubMedId": null,
                    "title": "Sprycel (dasatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11538,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AIC-47 and Gleevec (imatinib mesylate) synergistically inhibited Bcr-Abl1 expression, induced apoptosis in chronic myeloid leukemia cell lines (PMID: 26607903).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 6021,
                "therapyName": "AIC-47 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9607,
                    "pubMedId": 26607903,
                    "title": "Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26607903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16864,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, UM-9107 demonstrated activity against BCR-ABL1 in chronic myeloid leukemia cell lines in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1327).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 8212,
                "therapyName": "UM-9107",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14985,
                    "pubMedId": null,
                    "title": "UM-9107:A selective wild-type and T315I Bcr-Abl inhibitor with in vivo activity against chronic myelogenous leukemia.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10356,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Asciminib (ABL001) treatment demonstrated safety and efficacy, resulted in more than 1-log reduction in BCR-ABL1 in 65% (11/17) and major molecular response in 29% (5/17) of TKI-resistant chronic myeloid leukemia patients with baseline BCR-ABL1 > 0.1 %, and major cytogenetic response in 82% (9/11) of TKI-resistant patients in cytogenetic relapse (Blood 2015 126:1380).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8366,
                    "pubMedId": null,
                    "title": "ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy",
                    "url": "http://www.bloodjournal.org/content/126/23/138"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10560,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited growth of BCR-ABL1 positive chronic myeloid leukemia cells in culture, resulted in complete regression in cell line xenograft models (PMID: 28329763).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13393,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is included in the guidelines for patients with relapsed or refractory BCR-ABL1-positive acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6246,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, chronic myeloid leukemia patients with a low BCR-ABL1 transcript level (<10%) and fast BCR-ABL1 transcript elimination rate (halving time less than or equal to 17 days) responded best to tyrosine kinase inhibitor treatments including Gleevec (imatinib), Tasigna (nilotinib), or Sprycel (dasatinib) (PMID: 27131622).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5508,
                    "pubMedId": 27131622,
                    "title": "Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27131622"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18922,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is included in guidelines as a preferred regimen for patients with BCR-ABL1-positive chronic myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8435,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, Sprycel (dasatinib) and Tasigna (nilotinib) resulted in comparable clinical outcome in propensity score-matched chronic phase chronic myeloid leukemia patients (PMID: 27509035).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6656,
                    "pubMedId": 27509035,
                    "title": "A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27509035"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2005,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ENESTnd) that supported FDA approval, treatment with Tasigna (nilotinib) resulted in an improved rate of major molecular response of 44% for the 300mg dose and 43% for the 400mg dose compared to 22% with Gleevec (imatinib) and increased complete cytogenetic response rate (80% (300mg) or 78% (400mg) vs. 65%) in patients with Philadelphia chromosome (BCR-ABL1)-positive chronic myeloid leukemia (PMID: 20525993; NCT00471497).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10795,
                    "pubMedId": 20525993,
                    "title": "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20525993"
                },
                {
                    "id": 15477,
                    "pubMedId": null,
                    "title": "Tasigna (nilotinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13395,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Besponsa (inotuzumab ozogamicin) is included in the guidelines for adult and pediatric patients with relapsed or refractory BCR-ABL1-positive B-cell acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3199,
                "therapyName": "inotuzumab ozogamicin",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18919,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gleevec (imatinib) is included in guidelines for patients with BCR-ABL1-positive chronic myeloid leukemia (NCCN.org)",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1891,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in an improved progression-free survival rate compared to treatment with interferon-alfa plus low-dose cytarabine (92.1.% vs. 73.5% at 18 mo.), and higher estimated rates of complete hematologic response (96.8% vs. 69.0% at 18 mo.) major cytogenetic response (87.1% vs 34.7% at 18 mo.) in patients with newly-diagnosed Philadelphia chromosome (BCR-ABL1)-positive chronic myeloid leukemia (PMID: 12637609).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2377,
                    "pubMedId": 12637609,
                    "title": "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12637609"
                },
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6245,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, chronic myeloid leukemia patients with a low BCR-ABL1 transcript level (<10%) and fast BCR-ABL1 transcript elimination rate (halving time less than or equal to 17 days) responded best to tyrosine kinase inhibitor treatments including Gleevec (imatinib), Tasigna (nilotinib), or Sprycel (dasatinib) (PMID: 27131622).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5508,
                    "pubMedId": 27131622,
                    "title": "Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27131622"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5792,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 combination treatment did not inhibit growth of BCR-ABL1 transformed cell lines in culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3926,
                "therapyName": "Ruxolitinib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5798,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) combination treatment did not inhibit growth of BCR-ABL1 transformed cell lines in culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3927,
                "therapyName": "Pictilisib + Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) and Sprycel (dasatinib) combination treatment resulted in enhanced growth inhibition of chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 5561,
                "therapyName": "Asciminib + Dasatinib + Prednisone",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10729,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Serdemetan (JNJ-26854165) promoted BCR-ABL1 mRNA degradation, blocked downstream signaling, resulted in growth inhibition in chronic myeloid leukemia cells harboring BCR-ABL1 in culture and in cell line xenograft models (PMID: 27999193).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 2309,
                "therapyName": "Serdemetan",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8788,
                    "pubMedId": 27999193,
                    "title": "The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27999193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12337,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (BFORE) that supported FDA approval, treatment with Bosulif (bosutinib) demonstrated benefit over treatment with Gleevec (imatinib), resulting in an improved major molecular response rate at 12 months (47.2% vs 36.9%, p=0.02) and complete cytogenetic response rate at 12 months (77.2% vs 66.4%, p=0.0075) in BCR-ABL1-positive chronic myeloid leukemia patients (PMID: 29091516; NCT02130557).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10332,
                    "pubMedId": 29091516,
                    "title": "Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29091516"
                },
                {
                    "id": 15536,
                    "pubMedId": null,
                    "title": "Bosulif (bosutinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203341"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9635,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, long-term analysis of Philadelphia chromosome (BCR-ABL1)-positive chronic myeloid leukemia patients treated with Bosulif (bosutinib) demonstrated a median duration of response of 8.6 months, a 4-year cumulative confirmed complete hematological response rate of 74%, and a 4-year overall survival rate of 78% (PMID: 27531525).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7356,
                    "pubMedId": 27531525,
                    "title": "Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27531525"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2102,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial (Study 200) that supported FDA approval, Philadelphia chromosome positive chronic myeloid leukemia patients resistant or intolerant to Gleevec (imatinib) were treated with Bosulif (bosutinib), which resulted in a significant hematological response and at two years, a progression free survival of 79% and overall survival of 92% (PMID: 21865346; NCT00261846).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2625,
                    "pubMedId": 21865346,
                    "title": "Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21865346"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18921,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is included in guidelines as a preferred regimen for patients with BCR-ABL1-positive chronic myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12898,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AP23464 inhibited cell proliferation, blocked cell cycle progression, and led to apoptotic activity in an acute myeloid leukemia cell line harboring BCR-ABL1 in culture (PMID: 15256422).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19119,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BCR-ABL1 aids in the diagnosis of lymphoblastic lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 80147,
                "name": "lymphoblastic lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13394,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Blincyto (blinatumomab) is included in the guidelines for adult and pediatric patients with relapsed or refractory BCR-ABL1-positive B-cell acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 1876,
                "therapyName": "Blinatumomab",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10649,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Blincyto (blinatumomab) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 36% (16/45) of Ph+ acute lymphocytic leukemia patients that progressed after tyrosine kinase inhibitor therapy (PMID: 28355115).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 1876,
                "therapyName": "Blinatumomab",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8708,
                    "pubMedId": 28355115,
                    "title": "Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28355115"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10555,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited growth of BCR-ABL1 transformed cells in culture, and was selectively active against BCR-ABL1 positive cell lines in a panel of 450 cancer cell lines (PMID: 28329763).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed mouse myeloid cells over expressing BCR-ABL1 demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 418,
                    "pubMedId": 21224473,
                    "title": "Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21224473"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10875,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of BGB-324 and Gleevec (imatinib) resulted in additive effect on growth inhibition in BCR-ABL1 positive chronic myeloid leukemia cell lines in culture (PMID: 27856601).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 5668,
                "therapyName": "BGB-324 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8873,
                    "pubMedId": 27856601,
                    "title": "Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27856601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9601,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) decreased Rb phosphorylation and induced apoptosis in BCR-ABL1-positive acute lymphocytic leukemia (ALL) cell lines in culture, and demonstrated anti-leukemic activity in BCR-ABL1-positive ALL cell line xenograft models (PMID: 26637365).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7316,
                    "pubMedId": 26637365,
                    "title": "Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9049,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, chronic myeloid leukemia cells dependent on BCL-ABL1 activity demonstrated minimal sensitivity to Venclexta (venetoclax) in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5810,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of BCR-ABL1 transformed cell lines in culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3929,
                "therapyName": "Ruxolitinib + TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13396,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Kymriah (tisagenlecleucel) is included in the guidelines for adult and pediatric patients with relapsed or refractory BCR-ABL1-positive B-cell acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 5981,
                "therapyName": "Tisagenlecleucel",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10726,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of PD180970 and Serdemetan (JNJ-26854165) synergistically inhibited growth of chronic myeloid leukemia cells harboring BCR-ABL1 in culture and suppressed tumor growth, prolonged survival in cell line xenograft models (PMID: 27999193).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 5601,
                "therapyName": "PD180970 + Serdemetan",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8788,
                    "pubMedId": 27999193,
                    "title": "The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27999193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1884,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE) that supported FDA approval, Iclusig (ponatinib) resulted in a hematological response in 41% and a major cytogenetic response in 47% of patients with Philadelphia chromosome (BCR-ABL1)-positive acute lymphoblastic leukemia (PMID: 24180494, PMID: 23935038; NCT01207440).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1037,
                "name": "lymphoid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2374,
                    "pubMedId": 23935038,
                    "title": "Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23935038"
                },
                {
                    "id": 5465,
                    "pubMedId": 24180494,
                    "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24180494"
                },
                {
                    "id": 15534,
                    "pubMedId": null,
                    "title": "Iclusig (ponatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) and Tasigna (nilotinib) combination treatment resulted in enhanced growth inhibition of chronic myeloid leukemia cells harboring BCR-ABL1 in culture and durable tumor regression in cell line xenograft models (PMID: 28329763).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 5560,
                "therapyName": "Asciminib + Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15072,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, STRO-001 inhibited growth of Ph-positive acute lymphocytic leukemia cells in culture (Blood 2016 128 (22):464).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 7413,
                "therapyName": "STRO-001",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12622,
                    "pubMedId": null,
                    "title": "Targeting CD74 with Novel Antibody Drug Conjugates (ADCs) for the Treatment of B-Cell Non-Hodgkin's Lymphoma (NHL)",
                    "url": "http://www.bloodjournal.org/content/128/22/464?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9031,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial that supported FDA approval, Sprycel (dasatinib) treatment resulted in confirmed major hematological response in 38% (15/40) and 32% (14/32) in patients receiving once daily or twice daily treatment, respectively, a median duration of major hematological response of 4.6 months, and a median progression-free survival of 4.0 months in patients with BCR-ABL1-positive acute lymphoblastic leukemia BCR-ABL1 (PMID: 20131302; NCT00123487).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10782,
                    "pubMedId": 20131302,
                    "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20131302"
                },
                {
                    "id": 15535,
                    "pubMedId": null,
                    "title": "Sprycel (dasatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021986"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13387,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is included in guidelines for adult and pediatric patients with relapsed or refractory BCR-ABL1-positive acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10635,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) and Gleevec (imatinib) combination treatment resulted in enhanced growth inhibition of chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 5562,
                "therapyName": "Asciminib + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16911,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, HQP1351 treatment resulted in complete hematological response in 93% (65/70) of patients with chronic phase or accelerated phase chronic myeloid leukemia, with 76% of the patients (53/70) harboring BCR-ABL1 (Blood 2018 132:791).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 8237,
                "therapyName": "HQP1351",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15048,
                    "pubMedId": null,
                    "title": "Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor\u2014Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study",
                    "url": "http://www.bloodjournal.org/content/132/Suppl_1/791.abstract?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13392,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is included in the guidelines for patients with relapsed or refractory BCR-ABL1-positive acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18923,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iclusig (ponatinib) is included in guidelines as a preferred regimen for patients with accelerated phase BCR-ABL1-positive chronic myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6340,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in a major cytogenic regression in 56% (149/267) of patients with BCR-ABL1 positive chronic myeloid leukemia that had failed prior BCR-ABL1 targeting therapies (PMID: 26603839).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4961,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BP-1-108 inhibited phosphorylation of Stat5 and induced apoptosis in leukemia cells harboring BCR-ABL1 in cell culture (PMID: 22148584).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3703,
                "therapyName": "BP-1-108",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4812,
                    "pubMedId": 22148584,
                    "title": "Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22148584"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5804,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and BEZ235 combination treatment did not inhibit growth of BCR-ABL1 transformed cell lines in culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3928,
                "therapyName": "BEZ235 + Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5896,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PBA2 resulted in growth inhibition and terminal differentiation in a number of imatinib-resistant chronic myeloid leukemia cell lines harboring BCR-ABL1 mutations (AACR, Cancer Res: April 2016; Volume 57, Abstract #3915).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3975,
                "therapyName": "PBA2",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5187,
                    "pubMedId": null,
                    "title": "PBA2, a dual BCR-ABL and GSK3?kinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=d0cbfd99-0744-49e4-a827-562c416014d8&cKey=72e71da1-be1f-4d1d-9554-e10537c87463&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4585,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and SGI-1776 combination treatment did not inhibit proliferation of a myeloid cell line harboring BCR-ABL in culture (PMID: 26472029).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 3549,
                "therapyName": "Ruxolitinib + SGI-1776",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12319,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, Radotinib treatment resulted in an increases=d major molecular response rate (52% vs 30%, p=0.0044) and complete cytogenetic response rate (91% vs 77%, p=0.0120) compared to Gleevec (imatinib mesylate) in patients with Philadelphia chromosome-positive chronic myeloid leukemia (PMID: 28939746; NCT01511289).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 6454,
                "therapyName": "Radotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10324,
                    "pubMedId": 28939746,
                    "title": "Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28939746"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10563,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) treatment resulted in tumor regression in patient derived xenograft models of Ph+ acute lymphocytic leukemia (PMID: 28329763).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1895,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in complete hematologic response (CHR) in 19% (9/48), marrow complete response in 10% (5/48), and marrow partial response in 31% (15/48) of patients with refractory or relapsed Philadelphia chromosome (BCR-ABL1)-positive acute lymphoid leukemia, which lasted at least 4 weeks in 27% (13/48; 3 CHRs) of patients (PMID: 12200353).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2378,
                    "pubMedId": 12200353,
                    "title": "A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12200353"
                },
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13388,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gleevec (imatinib) is included in the guidelines for adult and pediatric patients with relapsed or refractory BCR-ABL1-positive acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18089,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "BCR-ABL1 fusions (t(9;22)(q34.1;q11.2)) are associated with a poor/adverse prognosis in patients with non-APL acute myeloid leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13391,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iclusig (ponatinib) is included in the guidelines for patients with relapsed or refractory BCR-ABL1-positive acute lymphoblastic leukemia (NCCN.org).",
            "molecularProfile": {
                "id": 2513,
                "profileName": "BCR - ABL1"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18909,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 V299L (NCCN.org).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10582,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing the catalytic-site-resistant mutation ABL1 V299L in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18896,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 V299L (NCCN.org).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1820,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, BCR-ABL1 V299L was associated with resistance to Bosulif (bosutinib) in patients with chronic myeloid leukemia (PMID: 23086624).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2210,
                    "pubMedId": 23086624,
                    "title": "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23086624"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20121,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 V299L (NCCN.org).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1821,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a V299L mutation in BCR-ABL1 conferred resistance to Bosulif (bosutinib) in cell culture (PMID: 19075254).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2214,
                    "pubMedId": 19075254,
                    "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19075254"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20129,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 V299L (NCCN.org).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6253,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 37.5% (3/8) of chronic myeloid leukemia patients harboring ABL1 V299L in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20993,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 V299L in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 3598,
                "profileName": "BCR - ABL1 ABL1 V299L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20938,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited survival of transformed cells expressing ABL1 T315I in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18911,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 T315I (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10631,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, chronic myeloid leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 were resistant to Tasigna (nilotinib) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10384,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Danusertib (PHA-739358) treatment resulted in complete response in one and partial response in another patient with Philadelphia chromosome-positive acute lymphoblastic leukemia harboring ABL1 T315I in the context of BCR-ABL1 (PMID: 25887498).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 716,
                "therapyName": "Danusertib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8407,
                    "pubMedId": 25887498,
                    "title": "A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25887498"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11456,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE) that supported FDA approval, Iclusig (ponatinib) resulted in a major cytogenetic response in 41% of acute lymphocytic leukemia patients harboring ABL1 T315I in the context of BCR-ABL1 (PMID: 24180494; NCT01207440).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5465,
                    "pubMedId": 24180494,
                    "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24180494"
                },
                {
                    "id": 15534,
                    "pubMedId": null,
                    "title": "Iclusig (ponatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13450,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iclusig (ponatinib) is included in the guidelines for relapsed or refractory acute lymphoblastic leukemia patients with BCR-ABL1 and ABL1 T315I (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18905,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 T315I (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5897,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PBA2 resulted in growth inhibition and terminal differentiation in a number of imatinib-resistant chronic myeloid leukemia cell lines harboring BCR-ABL1 T315I (AACR, Cancer Res: April 2016; Volume 57, Abstract #3915).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 3975,
                "therapyName": "PBA2",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5187,
                    "pubMedId": null,
                    "title": "PBA2, a dual BCR-ABL and GSK3?kinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=d0cbfd99-0744-49e4-a827-562c416014d8&cKey=72e71da1-be1f-4d1d-9554-e10537c87463&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10602,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing ABL1 T315I in the context of BCR-ABL1 were resistant to Sprycel (dasatinib) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6208,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE) that supported FDA approval, Iclusig (ponatinib) resulted in a major cytogenetic response in 70% of chronic myeloid leukemia patients harboring ABL1 T315I in the context of BCR-ABL1 (PMID: 24180494; NCT01207440).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5465,
                    "pubMedId": 24180494,
                    "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24180494"
                },
                {
                    "id": 15534,
                    "pubMedId": null,
                    "title": "Iclusig (ponatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203469"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10831,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, chronic-phase chronic myeloid leukemia (CML) patients harboring BCR-ABL1 with ABL1 T315I demonstrated a higher overall survival (OS) at 48 months with Iclusig (ponatinib) treatment vs. allogeneic stem cell transplant (72.7% vs. 55.8%), however, OS did not differ in patients with accelerated-phase CML, and was shorter in patients with blast-crisis CML (PMID: 28387926).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8862,
                    "pubMedId": 28387926,
                    "title": "Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28387926"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18924,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Iclusig (ponatinib) is included in guidelines as a treatment option for patients with BCR-ABL1-positive chronic myeloid leukemia with ABL1 T315I, for whom no other tyrosine kinase inhibitors are indicated (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10382,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Danusertib (PHA-739358) treatment resulted in response in 20% (4/20) of patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to second generation c-Abl therapy, with all 4 patients harboring ABL1 T315I in the context of BCR-ABL1 (PMID: 25887498).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 716,
                "therapyName": "Danusertib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8407,
                    "pubMedId": 25887498,
                    "title": "A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25887498"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12902,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 T315I were resistant to AP23464 in culture (PMID: 15256422).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10650,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Blincyto (blinatumomab) treatment resulted in complete remission (CR) or CR with partial hematologic recovery in 40% (4/10) of Ph+ acute lymphocytic leukemia patients harboring ABL1 T315I, who progressed after prior tyrosine kinase inhibitor therapy (PMID: 28355115).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 1876,
                "therapyName": "Blinatumomab",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8708,
                    "pubMedId": 28355115,
                    "title": "Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28355115"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2134,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines expressing BCR-ABL T315I demonstrated sensitivity to Rebastinib (DCC-2036) (PMID: 21505103).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2618,
                    "pubMedId": 21505103,
                    "title": "The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21505103"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18910,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 T315I (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10383,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Danusertib (PHA-739358) treatment resulted in complete hematologic response in one and complete cytogenetic response in another patient with chronic myeloid leukemia harboring ABL1 T315I in the context of BCR-ABL1 (PMID: 25887498).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 716,
                "therapyName": "Danusertib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8407,
                    "pubMedId": 25887498,
                    "title": "A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25887498"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6477,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 T315I in the context of BCR-ABL1 was identified as a Gleevec (imatinib)-resistant mutation in 6 patients with BCR-ABL1 positive leukemia, and resistance was supported by a in vitro assay (PMID: 12399961).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9903,
                    "pubMedId": 12399961,
                    "title": "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12399961"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16912,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, HQP1351 treatment resulted in complete hematological response in 89% (40/45) of patients with chronic phase or accelerated phase chronic myeloid leukemia harboring ABL1 T315I in the context of BCR-ABL1 (Blood 2018 132:791).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 8237,
                "therapyName": "HQP1351",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15048,
                    "pubMedId": null,
                    "title": "Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor\u2014Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study",
                    "url": "http://www.bloodjournal.org/content/132/Suppl_1/791.abstract?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10576,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Asciminib (ABL001) treatment resulted in complete cytogenetic response in 43% (3/7) of chronic myeloid leukemia patients harboring ABL1 T315I in the context of BCR-ABL1 (ASH 58th Annual Meeting and Exposition, Dec 2016, abstract # 625).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8642,
                    "pubMedId": null,
                    "title": "Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy",
                    "url": "https://ash.confex.com/ash/2016/webprogram/Paper92633.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10629,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited growth of chronic myeloid leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1, resulted in tumor regression in cell line xenograft models (PMID: 28329763).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20943,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 T315I in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20124,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 T315I (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2103,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 T315I was identified in 6 of 11 patients with BCR-ABL1-positive chronic myeloid leukemia with acquired resistance to Gleevec (imatinib), and resistance was confirmed in cell culture (PMID: 11423618).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2379,
                    "pubMedId": 11423618,
                    "title": "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11423618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10601,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing ABL1 T315I in the context of BCR-ABL1 were resistant to Tasigna (nilotinib) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10730,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Serdemetan (JNJ-26854165) promoted BCR-ABL1 mRNA degradation, blocked downstream signaling, resulted in growth inhibition in leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 in culture and in cell line xenograft models (PMID: 27999193).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2309,
                "therapyName": "Serdemetan",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8788,
                    "pubMedId": 27999193,
                    "title": "The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27999193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20120,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 T315I (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10731,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of PD180970 and Serdemetan (JNJ-26854165) did not demonstrate improved growth inhibition compared to Serdemetan (JNJ-26854165) alone in leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 in culture and in cell line xenograft models (PMID: 27999193).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 5601,
                "therapyName": "PD180970 + Serdemetan",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8788,
                    "pubMedId": 27999193,
                    "title": "The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27999193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10754,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rebastinib (DCC-2036) resulted in a complete hematological response and partial hematological response in 50% (4/8) and 75% (3/4) of chronic myeloid leukemia patients harboring BCR-ABL1 ABL1 T315I, respectively (PMID: 27927766).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8807,
                    "pubMedId": 27927766,
                    "title": "Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27927766"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6264,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TG101209 blocked BCR-ABL-independent signaling and induced cell-cycle arrest in cells expressing BCR-ABL1 with ABL1 T315I in culture, and prolonged survival in a mouse cell line xenograft model of chronic myeloid leukemia expressing BCR-ABL1 with ABL1 T315I (PMID: 26846820).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2403,
                "therapyName": "TG101209",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5513,
                    "pubMedId": 26846820,
                    "title": "Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26846820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10728,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD180970 did not inhibit growth of leukemia cells harboring ABL1 T315I in the context of BCR-ABL1 in culture (PMID: 27999193).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2610,
                "therapyName": "PD180970",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8788,
                    "pubMedId": 27999193,
                    "title": "The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27999193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2136,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a leukemia cell line harboring the Gleevec (imatinib) resistant mutation, BCR-ABL T315I, demonstrated sensitivity to KW-2449 (PMID: 19541823).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2614,
                "therapyName": "KW-2449",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2612,
                    "pubMedId": 19541823,
                    "title": "KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19541823"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20131,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 T315I (NCCN.org).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9602,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute lymphocytic leukemia (ALL) cell lines harboring BCR-ABL1 with ABL1 T315I demonstrated sensitivity to Ibrance (palbociclib) in culture, and treatment with Ibrance (palbociclib) decreased Rb phosphorylation and improved survival in cell line xenograft models of BCR-ABL1-positive ALL with ABL1 T315I (PMID: 26637365).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7316,
                    "pubMedId": 26637365,
                    "title": "Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637365"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19142,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 T315I in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10581,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing the catalytic-site-resistant mutation ABL1 T315I in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11922,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 with an ABL1 T315I mutation demonstrated resistance to treatment with Gleevec (imatinib) in culture (PMID: 11423618).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2379,
                    "pubMedId": 11423618,
                    "title": "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11423618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10876,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB-324 inhibited growth, induced apoptosis in chronic myeloid leukemia cells harboring ABL1 T315I in the context of BCR-ABL1 in culture, reduced tumor growth in cell line xenograft models (PMID: 27856601).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 2660,
                "therapyName": "BGB-324",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8873,
                    "pubMedId": 27856601,
                    "title": "Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27856601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combination of Gleevec (imatinib) and Serdemetan (JNJ-26854165) did not demonstrate improved growth inhibition compared to Serdemetan (JNJ-26854165) alone in leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 in culture (PMID: 27999193).",
            "molecularProfile": {
                "id": 5358,
                "profileName": "BCR - ABL1 ABL1 T315I"
            },
            "therapy": {
                "id": 5602,
                "therapyName": "Imatinib + Serdemetan",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 8788,
                    "pubMedId": 27999193,
                    "title": "The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27999193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11925,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 E255K in the context of BCR-ABL1 was associated with resistance to Gleevec (imatinib) in patients with BCR-ABL1-positive leukemia, and resistance was confirmed in a kinase assay (PMID: 12399961).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9903,
                    "pubMedId": 12399961,
                    "title": "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12399961"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18913,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 E255K (NCCN.org).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2107,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited cell growth of transformed cells expressing BCR-ABL1 E255K in culture and in cell line xenograft models (PMID: 16105974).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2628,
                    "pubMedId": 16105974,
                    "title": "NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16105974"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12901,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 E255K demonstrated a decreased response to treatment with AP23464 in culture compared to cells co-expressing BCR-ABL1 and other ABL1 mutations such as ABL1 Q252H and ABL1 Y253F (PMID: 15256422).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2108,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing BCR-ABL E255K demonstrated resistance to Gleevec (imatinib) (PMID: 15194504).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2626,
                    "pubMedId": 15194504,
                    "title": "The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15194504"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6250,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 61.5% (8/13) of chronic myeloid leukemia patients harboring ABL1 E255K in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10587,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing the catalytic-site-resistant mutation ABL1 E255K in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20133,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 E255K (NCCN.org).",
            "molecularProfile": {
                "id": 5391,
                "profileName": "BCR - ABL1 ABL1 E255K"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18907,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F317L (NCCN.org).",
            "molecularProfile": {
                "id": 22836,
                "profileName": "BCR - ABL1 ABL1 F317L"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6248,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 45% (13/29) of chronic myeloid leukemia patients harboring ABL1 F317L in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22836,
                "profileName": "BCR - ABL1 ABL1 F317L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18900,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F317L (NCCN.org).",
            "molecularProfile": {
                "id": 22836,
                "profileName": "BCR - ABL1 ABL1 F317L"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20923,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 F317L in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 22836,
                "profileName": "BCR - ABL1 ABL1 F317L"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20944,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 F317L in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 22836,
                "profileName": "BCR - ABL1 ABL1 F317L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20123,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F317L (NCCN.org).",
            "molecularProfile": {
                "id": 22836,
                "profileName": "BCR - ABL1 ABL1 F317L"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20126,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F317L (NCCN.org).",
            "molecularProfile": {
                "id": 22836,
                "profileName": "BCR - ABL1 ABL1 F317L"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6249,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 55% (11/20) of chronic myeloid leukemia patients harboring ABL1 F359V in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22837,
                "profileName": "BCR - ABL1 ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20991,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 F359V in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 22837,
                "profileName": "BCR - ABL1 ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20135,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 E359V (NCCN.org).",
            "molecularProfile": {
                "id": 22837,
                "profileName": "BCR - ABL1 ABL1 F359V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19159,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 F359V demonstrated resistance to inhibition of proliferation and BCR-ABL1 phosphorylation by Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22837,
                "profileName": "BCR - ABL1 ABL1 F359V"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18915,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F359V (NCCN.org).",
            "molecularProfile": {
                "id": 22837,
                "profileName": "BCR - ABL1 ABL1 F359V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18918,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6251,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 67% (8/12) of chronic myeloid leukemia patients harboring ABL1 G250E in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20138,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 G250E in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18897,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20122,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Bosulif (bosutinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 G250E (NCCN.org).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20995,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 G250E in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 22838,
                "profileName": "BCR - ABL1 ABL1 G250E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11926,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 M244V was associated with resistance to Gleevec (imatinib) in patients with BCR-ABL1-positive chronic myeloid leukemia (PMID: 17189410).",
            "molecularProfile": {
                "id": 22839,
                "profileName": "BCR - ABL1 ABL1 M244V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9909,
                    "pubMedId": 17189410,
                    "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17189410"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6252,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 56% (4/9) of chronic myeloid leukemia patients harboring ABL1 M244V in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22839,
                "profileName": "BCR - ABL1 ABL1 M244V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18697,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Bosulif (bosutinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18695,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Tasigna (nilotinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19144,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 H396R in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18698,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated moderate resistance to Rebastinib (DCC-2036) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18696,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Sprycel (dasatinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18693,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated resistance to Gleevec (imatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18694,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 H396R in the context of BCR-ABL1 demonstrated sensitivity to Iclusig (ponatinib) in culture, resulting in decreased cell viability (PMID: 25132497).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6256,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 20% (1/5) and major molecular response in 40% (2/5) of chronic myeloid leukemia patients harboring ABL1 H396R in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ABL1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22840,
                "profileName": "BCR - ABL1 ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10589,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing the catalytic-site-resistant mutation ABL1 E255V in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 22841,
                "profileName": "BCR - ABL1 ABL1 E255V"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19141,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 E255V in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22841,
                "profileName": "BCR - ABL1 ABL1 E255V"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20134,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 E255V (NCCN.org).",
            "molecularProfile": {
                "id": 22841,
                "profileName": "BCR - ABL1 ABL1 E255V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18914,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 E255V (NCCN.org).",
            "molecularProfile": {
                "id": 22841,
                "profileName": "BCR - ABL1 ABL1 E255V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6258,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 25% (1/4) of chronic myeloid leukemia patients harboring ABL1 F359V in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22841,
                "profileName": "BCR - ABL1 ABL1 E255V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20994,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 E255V in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 22841,
                "profileName": "BCR - ABL1 ABL1 E255V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11924,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 E255V in the context of BCR-ABL1 was associated with resistance to Gleevec (imatinib) in a patient with BCR-ABL1-positive leukemia, and resistance was confirmed in a kinase assay (PMID: 12399961).",
            "molecularProfile": {
                "id": 22841,
                "profileName": "BCR - ABL1 ABL1 E255V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9903,
                    "pubMedId": 12399961,
                    "title": "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12399961"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20136,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F359I (NCCN.org).",
            "molecularProfile": {
                "id": 22966,
                "profileName": "BCR - ABL1 ABL1 F359I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6254,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 75% (3/4) of chronic myeloid leukemia patients harboring ABL1 F359V in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ABL1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22966,
                "profileName": "BCR - ABL1 ABL1 F359I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18917,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F359I (NCCN.org).",
            "molecularProfile": {
                "id": 22966,
                "profileName": "BCR - ABL1 ABL1 F359I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 F359I demonstrated resistance to inhibition of proliferation and BCR-ABL1 phosphorylation by Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22966,
                "profileName": "BCR - ABL1 ABL1 F359I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6259,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 L248V in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22967,
                "profileName": "BCR - ABL1 ABL1 L248V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16828,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, ABL1 L284V in the context of BCR-ABL1 was identified in a chronic myeloid leukemia patient who failed Gleevec (imatinib) treatment (PMID: 27217448; NCT00481247).",
            "molecularProfile": {
                "id": 22967,
                "profileName": "BCR - ABL1 ABL1 L248V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14946,
                    "pubMedId": 27217448,
                    "title": "Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27217448"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16826,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 L284V in the context of BCR-ABL1 was identified in a chronic myeloid leukemia patient who demonstrated resistance to Gleevec (imatinib) treatment (PMID: 23062378).",
            "molecularProfile": {
                "id": 22967,
                "profileName": "BCR - ABL1 ABL1 L248V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14945,
                    "pubMedId": 23062378,
                    "title": "Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23062378"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6260,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 100% (2/2) of chronic myeloid leukemia patients harboring ABL1 Q252H in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22968,
                "profileName": "BCR - ABL1 ABL1 Q252H"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16837,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 Q252H in the context of BCR-ABL1 was identified in chronic myeloid leukemia patients who relapsed on Gleevec (imatinib) treatment (PMID: 12204532).",
            "molecularProfile": {
                "id": 22968,
                "profileName": "BCR - ABL1 ABL1 Q252H"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14949,
                    "pubMedId": 12204532,
                    "title": "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12204532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12899,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 Q252H were sensitive to treatment with AP23464 in culture, demonstrating cell growth inhibition and induction of apoptosis (PMID: 15256422).",
            "molecularProfile": {
                "id": 22968,
                "profileName": "BCR - ABL1 ABL1 Q252H"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18912,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 Y253H (NCCN.org).",
            "molecularProfile": {
                "id": 22969,
                "profileName": "BCR - ABL1 ABL1 Y253H"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10588,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing the catalytic-site-resistant mutation ABL1 Y253H in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 22969,
                "profileName": "BCR - ABL1 ABL1 Y253H"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19140,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Asciminib (ABL001) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 Y253H in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 22969,
                "profileName": "BCR - ABL1 ABL1 Y253H"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6476,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 Y253H in the context of BCR-ABL1 was associated with resistance to Gleevec (imatinib) in 4 patients with BCR-ABL1-positive leukemia that progressed on Gleevec (imatinib), and resistance was supported by a cell culture assay (PMID: 11853795).",
            "molecularProfile": {
                "id": 22969,
                "profileName": "BCR - ABL1 ABL1 Y253H"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9910,
                    "pubMedId": 11853795,
                    "title": "BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11853795"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20132,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 Y253H (NCCN.org).",
            "molecularProfile": {
                "id": 22969,
                "profileName": "BCR - ABL1 ABL1 Y253H"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6261,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 F359V in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22969,
                "profileName": "BCR - ABL1 ABL1 Y253H"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6262,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major molecular response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 E279K in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22970,
                "profileName": "BCR - ABL1 ABL1 E279K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6263,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 M351T in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22971,
                "profileName": "BCR - ABL1 ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12903,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 M351T were sensitive to treatment with AP23464 in culture, demonstrating cell growth inhibition and induction of apoptosis (PMID: 15256422).",
            "molecularProfile": {
                "id": 22971,
                "profileName": "BCR - ABL1 ABL1 M351T"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16830,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 M351T in the context of BCR-ABL1 was identified in 2 BCR-ABL1-positive chronic myeloid leukemia patients who demonstrated resistance to Gleevec (imatinib) treatment (PMID: 24456693).",
            "molecularProfile": {
                "id": 22971,
                "profileName": "BCR - ABL1 ABL1 M351T"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5511,
                    "pubMedId": 24456693,
                    "title": "BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24456693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16841,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 M351T in the context of BCR-ABL1 was identified in a BCR-ABL1-positive chronic myeloid leukemia patient who relapsed on Gleevec (imatinib) treatment (PMID: 12399961).",
            "molecularProfile": {
                "id": 22971,
                "profileName": "BCR - ABL1 ABL1 M351T"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9903,
                    "pubMedId": 12399961,
                    "title": "Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12399961"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12904,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 H396P were sensitive to treatment with AP23464 in culture, demonstrating cell growth inhibition and induction of apoptosis (PMID: 15256422).",
            "molecularProfile": {
                "id": 22972,
                "profileName": "BCR - ABL1 ABL1 H396P"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6341,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 H396P in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22972,
                "profileName": "BCR - ABL1 ABL1 H396P"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7995,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359V (91%), and F359V/M244V (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 22973,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7990,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) treatment resulted in a complete cytogenetic response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 T315I (93%) and T315I/E275D (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 22975,
                "profileName": "BCR - ABL1 ABL1 E275D ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6375,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) resulted in a partial cytogenic regression in a patient with heavily pretreated chronic myeloid leukemia expressing BCR-ABL1, ABL1 F317L, and E450G in a majority of BCR-ABL1 positive clones (PMID: 26603839).",
            "molecularProfile": {
                "id": 22977,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 E450G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6376,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) resulted in a major molecular response in a patient with heavily pretreated chronic myeloid leukemia expressing BCR-ABL1, ABL1 F359I, and T277I in a minority of BCR-ABL1 positive clones (PMID: 26603839).",
            "molecularProfile": {
                "id": 22978,
                "profileName": "BCR - ABL1 ABL1 T277I ABL1 F359I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7993,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 V299L (95%), and V299L/P310L (2%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 22982,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 P310L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6255,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 43% (3/7) of chronic myeloid leukemia patients harboring ABL1 E459K in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 22987,
                "profileName": "BCR - ABL1 ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10586,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing the catalytic-site-resistant mutation ABL1 E459K in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 22987,
                "profileName": "BCR - ABL1 ABL1 E459K"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20988,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 E459K in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 22987,
                "profileName": "BCR - ABL1 ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6257,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 14% (1/7) of chronic myeloid leukemia patients harboring ABL1 F359C in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 23080,
                "profileName": "BCR - ABL1 ABL1 F359C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18916,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F359C (NCCN.org).",
            "molecularProfile": {
                "id": 23080,
                "profileName": "BCR - ABL1 ABL1 F359C"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20137,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tasigna (nilotinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F359C (NCCN.org).",
            "molecularProfile": {
                "id": 23080,
                "profileName": "BCR - ABL1 ABL1 F359C"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6339,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 E355A in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 23082,
                "profileName": "BCR - ABL1 ABL1 E355A"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6342,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) resulted in major cytogenetic response in 50% (1/2) of chronic myeloid leukemia patients harboring ABL1 M473I in the context of BCR-ABL1, that had failed prior therapies targeting BCR-ALB1 (PMID: 26603839).",
            "molecularProfile": {
                "id": 23130,
                "profileName": "BCR - ABL1 ABL1 M437I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7996,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in 2 chronic myeloid leukemia patients harboring compound mutations including ABL1 F317L/E459K in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23131,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20960,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 E459K and F317L in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 23131,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20917,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 F317L and E549K in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 23131,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 E459K"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6387,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) resulted in a major molecular response in a patient with heavily pretreated chronic myeloid leukemia expressing BCR-ABL1, ABL1 Y253H, and ABL1 E282D in a minority of BCR-ABL1 positive clones (PMID: 26603839).",
            "molecularProfile": {
                "id": 23139,
                "profileName": "BCR - ABL1 ABL1 Y253H ABL1 E282D"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 7978,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 H396R (88%), and H396R/V299L (5%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23148,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7985,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 H396R/V299L (97%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23148,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 F359C demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 23152,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359C"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7983,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in complete cytogenetic response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 T315I/F317L (34%) and T315I (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23154,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 F317L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7986,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a complete cytogenetic response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359V/V299L (97%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23157,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7987,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a complete cytogenetic response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 G250E (27%) and G250E/E279V (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23161,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 E279V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16834,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 L384M in the context of BCR-ABL1 was identified in a BCR-ABL1-positive chronic myeloid leukemia (CML) with chronic phase CML with hematologic response but no cytogenetic response on Gleevec (imatinib) treatment (PMID: 12204532).",
            "molecularProfile": {
                "id": 23171,
                "profileName": "BCR - ABL1 ABL1 V379I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14949,
                    "pubMedId": 12204532,
                    "title": "Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12204532"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6379,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Iclusig (ponatinib) resulted in a major molecular response in a patient with heavily pretreated chronic myeloid leukemia expressing BCR-ABL1, ABL1 M244V, and ABL1 G250W in a minority of BCR-ABL1 positive clones (PMID: 26603839).",
            "molecularProfile": {
                "id": 23172,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8000,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 T315I (65%), and T315I/M237V (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 23174,
                "profileName": "BCR - ABL1 ABL1 M237V ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20990,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 L384M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 23537,
                "profileName": "BCR - ABL1 ABL1 L384M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16824,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 L384M in the context of BCR-ABL1 was identified in a BCR-ABL1-positive chronic myeloid leukemia patient who relapsed on Gleevec (imatinib) treatment (PMID: 16461309).",
            "molecularProfile": {
                "id": 23537,
                "profileName": "BCR - ABL1 ABL1 L384M"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14931,
                    "pubMedId": 16461309,
                    "title": "The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16461309"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20989,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 23538,
                "profileName": "BCR - ABL1 ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16825,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 L387M in the context of BCR-ABL1 was identified in a BCR-ABL1-positive chronic myeloid leukemia patient who demonstrated resistance to Gleevec (imatinib) treatment (PMID: 24456693).",
            "molecularProfile": {
                "id": 23538,
                "profileName": "BCR - ABL1 ABL1 L387M"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5511,
                    "pubMedId": 24456693,
                    "title": "BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24456693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16832,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression ABL1 M388L in the context of BCR-ABL1 conferred resistance to Gleevec (imatinib) in cultured cells (PMID: 15459011).",
            "molecularProfile": {
                "id": 23540,
                "profileName": "BCR - ABL1 ABL1 M388L"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11534,
                    "pubMedId": 15459011,
                    "title": "A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15459011"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16831,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 M388L in the context of BCR-ABL1 was identified in 2 patients with resistance to Gleevec (imatinib) treatment (PMID: 30082224).",
            "molecularProfile": {
                "id": 23540,
                "profileName": "BCR - ABL1 ABL1 M388L"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14495,
                    "pubMedId": 30082224,
                    "title": "Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30082224"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19194,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 T315L in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 23541,
                "profileName": "BCR - ABL1 ABL1 T315L"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6481,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 S417Y in the context of BCR-ABL1 was identified in patients with BCR-ABL1-positive leukemia (acute lymphocytic leukemia or chronic myeloid leukemia) with Gleevec (imatinib) resistance (PMID: 17189410).",
            "molecularProfile": {
                "id": 23543,
                "profileName": "BCR - ABL1 ABL1 S417Y"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9909,
                    "pubMedId": 17189410,
                    "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17189410"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1382,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, a Philadelphia chromosome (BCR-ABL1) positive chronic myeloid leukemia patient harboring ABL1 V289F demonstrated resistance to Gleevec (imatinib) (PMID: 23355941).",
            "molecularProfile": {
                "id": 23606,
                "profileName": "BCR - ABL1 ABL1 V289F"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1112,
                    "pubMedId": 23355941,
                    "title": "Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23355941"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7269,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IBR2 inhibited Rad51 function and induced apoptosis in transformed cells over expressing BCR-ABL1 T315I in culture (PMID: 23341130).",
            "molecularProfile": {
                "id": 24816,
                "profileName": "BCR - ABL1 ABL1 T315I RAD51 pos"
            },
            "therapy": {
                "id": 4429,
                "therapyName": "IBR2",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6267,
                    "pubMedId": 23341130,
                    "title": "A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23341130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7280,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of LYN Y508F conferred resistance to Gleevec (imatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 15175350).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6296,
                    "pubMedId": 15175350,
                    "title": "A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15175350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7288,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7290,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7289,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7291,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7287,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 and expressing LYN Y508F in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24962,
                "profileName": "BCR - ABL1 LYN Y508F"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7283,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Tasigna (nilotinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7284,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Iclusig (ponatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7286,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 with over expression of Gab2 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7282,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Sprycel (dasatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7285,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) decreased viability of chronic myeloid leukemia cells harboring BCR-ABL1 with over expression of Gab2 in culture (PMID: 26912052).",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7281,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of Gab2 conferred resistance to Gleevec (imatinib) in chronic myeloid leukemia cells harboring BCR-ABL1 in culture (PMID: 26912052)",
            "molecularProfile": {
                "id": 24966,
                "profileName": "BCR - ABL1 GAB2 over exp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6300,
                    "pubMedId": 26912052,
                    "title": "Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26912052"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7977,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations consisted of ABL1 V379I (90%), V379I/H396P (3%), and V379I/H396P (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26122,
                "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7979,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations consisted of F359C/T315I (76%), F359C (12%), and F359C/V299L (9%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26123,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 T315I ABL1 F359C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7980,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359V (82%), T315I (3%), and F359V/E255K (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26124,
                "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7981,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in a clinical response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359C/F317L (73%), F359C/T315I (21%), and F359C (3%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26125,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 F317L ABL1 F359C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7982,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment did not result in clinical response in a chronic myeloid leukemia patient harboring compound mutations consisted of ABL1 Y253H (94%), and G250E/F317L (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26126,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 Y253H ABL1 F317L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7984,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F317L/H396R (75%), F317L/E279K (20%), F317L/E281K (2%), and F317L (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26127,
                "profileName": "BCR - ABL1 ABL1 E279K ABL1 E281K ABL1 F317L ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7988,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations consisted of ABL1 T315I (95%), T315I/I432M (2%), and T315I/R386M (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26128,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 R386M ABL1 I432M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7991,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a partial cytogenetic response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F317L/E450G (92%) and F359V (6%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26129,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359V ABL1 E450G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7992,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359I (84%), F359I/T277I (2%), G250E (1%), and E507G (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26130,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T277I ABL1 F359I ABL1 E507G"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7994,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 M244V (89%), F359V (3%), and M244V/G250W (2%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26131,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7997,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 T315I (92%), C475W (1%), and T315I/K262N (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26132,
                "profileName": "BCR - ABL1 ABL1 K262N ABL1 T315I ABL1 C475W"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7998,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 F359V (60%), T315I (29%), F359V/M237R (2%), and F359V/R362T (2%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26133,
                "profileName": "BCR - ABL1 ABL1 M237R ABL1 T315I ABL1 F359V ABL1 R362T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8001,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (PACE), Iclusig (ponatinib) treatment resulted in a major molecular response in a chronic myeloid leukemia patient harboring compound mutations including ABL1 Y253H (96%), Y253H/A287V (1%), Y253H/E282D (1%), and Y456C (1%) in the context of BCR-ABL1, although further analysis suggested no correlation between mutation profile and Iclusig (ponatinib) response (PMID: 26603839; NCT01207440).",
            "molecularProfile": {
                "id": 26134,
                "profileName": "BCR - ABL1 ABL1 Y253H ABL1 E282D ABL1 A287V ABL1 Y456C"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 5509,
                    "pubMedId": 26603839,
                    "title": "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603839"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8335,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 E255K and T315I in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26231,
                "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8336,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 E255V and T315I in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26232,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8338,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia (CML) patients harboring BCR-ABL1 and expressing Bcl2 in culture, and inhibited tumor growth in Bcl2 positive, BCR-ABL1-driven animal models of CML (PMID: 27605552).",
            "molecularProfile": {
                "id": 26233,
                "profileName": "BCR - ABL1 BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8337,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically induced apoptosis in leukemia cells derived from Tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia patients harboring ABL1 H396R in the context of BCR-ABL1, and expressing Bcl2 in culture (PMID: 27605552).",
            "molecularProfile": {
                "id": 26234,
                "profileName": "BCR - ABL1 ABL1 H396R BCL2 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6621,
                    "pubMedId": 27605552,
                    "title": "Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27605552"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9066,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) inhibited growth and induced apoptosis in both patient-derived and established Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Gleevec (imatinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4867,
                "therapyName": "Imatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9070,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Iclusig (ponatinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4869,
                "therapyName": "Ponatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9069,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Tasigna (nilotinib) synergistically inhibited growth and induced apoptosis in Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4707,
                "therapyName": "Nilotinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9071,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and Sprycel (dasatinib) synergistically inhibited growth and induced apoptosis in patient-derived, Philadelphia chromosome-positive acute lymphocytic leukemia cells dependent on BCL-ABL1 activity, and with high Bcl2/Mcl1 ratio in culture, resulted in tumor inhibition in patient-derived xenograft models (PMID: 27582059).",
            "molecularProfile": {
                "id": 26700,
                "profileName": "BCR - ABL1 BCL2 pos MCL1 pos"
            },
            "therapy": {
                "id": 4868,
                "therapyName": "Dasatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6887,
                    "pubMedId": 27582059,
                    "title": "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27582059"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9603,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an acute lymphocytic leukemia cell line harboring BCR-ABL1 and loss of RB1 demonstrated decreased sensitivity to Ibrance (palbociclib) in culture (PMID: 26637365).",
            "molecularProfile": {
                "id": 26917,
                "profileName": "BCR - ABL1 RB1 loss"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7316,
                    "pubMedId": 26637365,
                    "title": "Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26637365"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10596,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells expressing ABL1 A337V in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 A337V in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10613,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing ABL1 A337V in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19162,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of cells expressing BCR-ABL1 with ABL1 A337V in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19163,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 A337V in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10607,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing ABL1 A337V in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19152,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 A337V demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10578,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 A337V in the context of BCR-ABL1 were resistant to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10619,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, chronic myeloid leukemia cells over expressing ABL1 A337V in the context of BCR-ABL1 were resistant to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10630,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of chronic myeloid leukemia cells over expressing ABL1 A337V in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27622,
                "profileName": "BCR - ABL1 ABL1 A337V"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 P465S in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10608,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing ABL1 P465S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10620,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABL1 P465S in the context of BCR-ABL1 was identified in chronic myeloid leukemia cells that acquired resistance to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10614,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing ABL1 P465S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19167,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 P465S in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10579,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 P465S in the context of BCR-ABL1 were resistant to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells expressing ABL1 P465S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 P465S in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27624,
                "profileName": "BCR - ABL1 ABL1 P465S"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19169,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 V468F in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10609,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells expressing ABL1 V468F in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10621,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABL1 V468F in the context of BCR-ABL1 was identified in chronic myeloid leukemia cells that acquired resistance to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19170,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 V468F in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10580,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells over expressing ABL1 V468F in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10615,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells expressing ABL1 V468F in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19171,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 V468F in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10585,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ABL1 V468F in the context of BCR-ABL1 were resistant to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19154,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 V468F demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 27628,
                "profileName": "BCR - ABL1 ABL1 V468F"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10593,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABL1 P223S in the context of BCR-ABL1 was identified in chronic myeloid leukemia cells that acquired resistance to Asciminib (ABL001) in culture and in cell line xenograft models (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10611,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells over expressing ABL1 P223S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10599,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells over expressing ABL1 P223S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells over expressing ABL1 P223S in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27641,
                "profileName": "BCR - ABL1 ABL1 P223S"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10590,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the allosteric inhibitor Asciminib (ABL001) inhibited growth of transformed cells expressing ABL1 G250H in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27644,
                "profileName": "BCR - ABL1 ABL1 G250H"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells over expressing ABL1 I502L in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27645,
                "profileName": "BCR - ABL1 ABL1 I502L"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10616,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells over expressing ABL1 I502L in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27645,
                "profileName": "BCR - ABL1 ABL1 I502L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10592,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABL1 I502L in the context of BCR-ABL1 was identified in chronic myeloid leukemia cells that acquired resistance to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27645,
                "profileName": "BCR - ABL1 ABL1 I502L"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10610,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells over expressing ABL1 I502L in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27645,
                "profileName": "BCR - ABL1 ABL1 I502L"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10612,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited growth of transformed cells over expressing ABL1 K294E in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27646,
                "profileName": "BCR - ABL1 ABL1 K294E"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10600,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells over expressing ABL1 K294E in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27646,
                "profileName": "BCR - ABL1 ABL1 K294E"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10618,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited growth of transformed cells over expressing ABL1 K294E in the context of BCR-ABL1 in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27646,
                "profileName": "BCR - ABL1 ABL1 K294E"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10594,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABL1 K294E in the context of BCR-ABL1 was identified in chronic myeloid leukemia cells that acquired resistance to Asciminib (ABL001) in culture (PMID: 28329763).",
            "molecularProfile": {
                "id": 27646,
                "profileName": "BCR - ABL1 ABL1 K294E"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 8633,
                    "pubMedId": 28329763,
                    "title": "The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28329763"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10668,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AKI603 inhibited Aurora kinase A activity and proliferation of chronic myeloid leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 in culture, resulted in tumor inhibition in cell line xenograft models (PMID: 27824120).",
            "molecularProfile": {
                "id": 27720,
                "profileName": "BCR - ABL1 ABL1 T315I AURKA pos"
            },
            "therapy": {
                "id": 4073,
                "therapyName": "AKI603",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8727,
                    "pubMedId": 27824120,
                    "title": "Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27824120"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AKI603 and Gleevec (imatinib) synergistically inhibited proliferation and colony formation in chronic myeloid leukemia cells over expressing ABL1 T315I in the context of BCR-ABL1 in culture (PMID: 27824120).",
            "molecularProfile": {
                "id": 27720,
                "profileName": "BCR - ABL1 ABL1 T315I AURKA pos"
            },
            "therapy": {
                "id": 5572,
                "therapyName": "AKI603 + Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8727,
                    "pubMedId": 27824120,
                    "title": "Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27824120"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11923,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, amplification of the BCR-ABL1 fusion was associated with acquired resistance to Gleevec (imatinib) in patients with chronic myeloid leukemia patients harboring BCR-ABL1 (PMID: 11423618).",
            "molecularProfile": {
                "id": 28357,
                "profileName": "BCR - ABL1 ABL1 amp BCR amp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2379,
                    "pubMedId": 11423618,
                    "title": "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11423618"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12900,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing BCR-ABL1 and ABL1 Y253F were sensitive to treatment with AP23464 in culture, demonstrating cell growth inhibition and induction of apoptosis (PMID: 15256422).",
            "molecularProfile": {
                "id": 28964,
                "profileName": "BCR - ABL1 ABL1 Y253F"
            },
            "therapy": {
                "id": 2593,
                "therapyName": "AP23464",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2591,
                    "pubMedId": 15256422,
                    "title": "Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15256422"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20992,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 F317V in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 29107,
                "profileName": "BCR - ABL1 ABL1 F317V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20127,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F317V (NCCN.org).",
            "molecularProfile": {
                "id": 29107,
                "profileName": "BCR - ABL1 ABL1 F317V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18898,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F317V (NCCN.org).",
            "molecularProfile": {
                "id": 29107,
                "profileName": "BCR - ABL1 ABL1 F317V"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20128,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 F317I (NCCN.org).",
            "molecularProfile": {
                "id": 29112,
                "profileName": "BCR - ABL1 ABL1 F317I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18899,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F317I (NCCN.org).",
            "molecularProfile": {
                "id": 29112,
                "profileName": "BCR - ABL1 ABL1 F317I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18908,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 F317C (NCCN.org).",
            "molecularProfile": {
                "id": 29116,
                "profileName": "BCR - ABL1 ABL1 F317C"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 18906,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in chronic myeloid leukemia patients with BCR-ABL1 harboring ABL1 T315A (NCCN.org).",
            "molecularProfile": {
                "id": 29118,
                "profileName": "BCR - ABL1 ABL1 T315A"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20125,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Sprycel (dasatinib) is not indicated for use in acute lymphoblastic leukemia patients with BCR-ABL1 harboring ABL1 T315A (NCCN.org).",
            "molecularProfile": {
                "id": 29118,
                "profileName": "BCR - ABL1 ABL1 T315A"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9952,
                "name": "acute lymphoblastic leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 15969,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Bosulif (bosutinib) resulted in decreased levels of BCR-ABL1 transcript after 7 weeks of treatment in an adult patient with Philadelphia chromosome (BCR-ABL1)-positive B-cell acute lymphoblastic leukemia harboring ABL1 Y440C, however, minimal residual disease remained (PMID: 30584318).",
            "molecularProfile": {
                "id": 31347,
                "profileName": "BCR - ABL1 ABL1 Y440C"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14104,
                    "pubMedId": 30584318,
                    "title": "A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30584318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15970,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an adult patient with Philadelphia chromosome (BCR-ABL1) positive B-cell acute lymphoblastic leukemia was found to have acquired an ABL1 Y440C mutation upon disease recurrence following Sprycel (dasatinib) therapy (PMID: 30584318).",
            "molecularProfile": {
                "id": 31347,
                "profileName": "BCR - ABL1 ABL1 Y440C"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14104,
                    "pubMedId": 30584318,
                    "title": "A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30584318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18704,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Gleevec (imatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20941,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited survival of transformed cells expressing both ABL1 T315I and ABL1 H396R in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20955,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 H396R and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18703,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Bosulif (bosutinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19198,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and T315I in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture, and treatment with Asciminib (ABL001) did not provide a survival benefit over vehicle control in xenograft models (PMID: 31543464)",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19203,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Asciminib (ABL001) to treatment with Iclusig (ponatinib) resulted in improved inhibition of proliferation compared to either agent alone in cells expressing ABL1 H396R and T315I in the context of BCR-ABL1 in culture, and improved survival and reduced tumor burden in xenograft models (PMID: 31543464).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 8935,
                "therapyName": "Asciminib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18702,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 H396R and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33503,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18860,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated sensitivity to Iclusig (ponatinib) in culture, resulting in decreased cell proliferation (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18856,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Gleevec (imatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Bosulif (bosutinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 690,
                "therapyName": "Bosutinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18861,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated sensitivity to Rebastinib (DCC-2036) in culture, resulting in decreased cell proliferation (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 1045,
                "therapyName": "Rebastinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18858,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M244V and ABL1 T315I in the context of BCR-ABL1 demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 25132497).",
            "molecularProfile": {
                "id": 33624,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11094,
                    "pubMedId": 25132497,
                    "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25132497"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19177,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tasigna (nilotinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 A344P in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33943,
                "profileName": "BCR - ABL1 ABL1 A344P"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19176,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sprycel (dasatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 A344P in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33943,
                "profileName": "BCR - ABL1 ABL1 A344P"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19158,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing BCR-ABL1 with ABL1 A344P demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33943,
                "profileName": "BCR - ABL1 ABL1 A344P"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19174,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cells expressing BCR-ABL1 with ABL1 A344P in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33943,
                "profileName": "BCR - ABL1 ABL1 A344P"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20922,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 G250E and T315I in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33944,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20945,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 G250E and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33944,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19190,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 G250E and T315I in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33944,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19199,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 T315I and Y253H in the context of BCR-ABL1 demonstrated resistance to Iclusig (ponatinib) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33945,
                "profileName": "BCR - ABL1 ABL1 Y253H ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19191,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 Y253H and T315I in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33945,
                "profileName": "BCR - ABL1 ABL1 Y253H ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19201,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Asciminib (ABL001) to treatment with Iclusig (ponatinib) resulted in restored efficacy and inhibition of BCR-ABL1 phosphorylation and proliferation in cells expressing ABL1 T315I and Y253H in the context of BCR-ABL1 in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33945,
                "profileName": "BCR - ABL1 ABL1 Y253H ABL1 T315I"
            },
            "therapy": {
                "id": 8935,
                "therapyName": "Asciminib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20950,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 G250E and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33946,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19200,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 E255V and T315I in the context of BCR-ABL1 demonstrated resistance to Iclusig (ponatinib) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33946,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19202,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Asciminib (ABL001) to treatment with Iclusig (ponatinib) resulted in restored efficacy and inhibition of BCR-ABL1 phosphorylation and proliferation in cells expressing ABL1 E255V and T315I in the context of BCR-ABL1 in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33946,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I"
            },
            "therapy": {
                "id": 8935,
                "therapyName": "Asciminib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20921,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 E255V and T3515I in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33946,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19192,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 E255V and T315I in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33946,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19193,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 M351T and T315I in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33947,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 M351T"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20981,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and E255V in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33948,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 V299L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19195,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 E255V and V299L in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33948,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 V299L"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20963,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 F317L and V299L in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33949,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 F317L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19196,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 F317L and V299L in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33949,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 F317L"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20958,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 F359V and F317L in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33950,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19197,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 F317L and F359V in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33950,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359V"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20919,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 F317L and F359V in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 33950,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359V"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19206,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Asciminib (ABL001) to treatment with Iclusig (ponatinib) resulted in restored efficacy and inhibition of BCR-ABL1 phosphorylation and proliferation in cells expressing ABL1 T315M in the context of BCR-ABL1 in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33952,
                "profileName": "BCR - ABL1 ABL1 T315M"
            },
            "therapy": {
                "id": 8935,
                "therapyName": "Asciminib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19205,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 T315M in the context of BCR-ABL1 demonstrated resistance to Iclusing (ponatinib) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33952,
                "profileName": "BCR - ABL1 ABL1 T315M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19204,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ABL1 T315M in the context of BCR-ABL1 demonstrated resistance to Asciminib (ABL001) in culture (PMID: 31543464).",
            "molecularProfile": {
                "id": 33952,
                "profileName": "BCR - ABL1 ABL1 T315M"
            },
            "therapy": {
                "id": 2484,
                "therapyName": "Asciminib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 16762,
                    "pubMedId": 31543464,
                    "title": "Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31543464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20959,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 L384M and F317L in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35405,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 L384M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20918,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 F317L and L384M in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35405,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 L384M"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20920,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 F317L and E255V in the context of BCR-ABL1 were resistant to Inlyta (axitinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35406,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 F317L"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20957,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 E255V and F317L in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35406,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 F317L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20939,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited survival of transformed cells expressing both ABL1 T315I and ABL1 L384M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35455,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 L384M"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20951,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 L384M and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35455,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 L384M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20953,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 L387M and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35456,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20940,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited survival of transformed cells expressing both ABL1 T315I and ABL1 L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35456,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 L387M"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20956,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 E459K and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35461,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20942,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited survival of transformed cells expressing both ABL1 T315I and ABL1 E459K in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35461,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 E459K"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20961,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 F317L and L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35462,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20962,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 F317L and M351T in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35463,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20967,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 F359V and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35464,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20968,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 F311L and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35465,
                "profileName": "BCR - ABL1 ABL1 F311L ABL1 T315I"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20974,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and E459K in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35466,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20975,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35467,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20976,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and L384M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35468,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 L384M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20977,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and M351T in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35469,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20978,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and L298V in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35471,
                "profileName": "BCR - ABL1 ABL1 L298V ABL1 V299L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20973,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ABL1 L298V was identified in a patient with Ph-positive (BCR-ABL1) chronic myeloid leukemia that was resistant to Gleevec (imatinib) treatment (PMID: 27868464).",
            "molecularProfile": {
                "id": 35472,
                "profileName": "BCR - ABL1 ABL1 L298V"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18218,
                    "pubMedId": 27868464,
                    "title": "Imatinib resistance in chronic myeloid leukemia due to a rare mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27868464"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20982,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and G250E in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35473,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 V299L"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20983,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 E255V and M351T in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35474,
                "profileName": "BCR - ABL1 ABL1 E255V ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20986,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 M244V and M351T in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35475,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20987,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 M244V and E459K in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35476,
                "profileName": "BCR - ABL1 ABL1 M244V ABL1 E459K"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20985,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 G250E and M351T in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35477,
                "profileName": "BCR - ABL1 ABL1 G250E ABL1 M351T"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20984,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 Y253H and F359V in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35478,
                "profileName": "BCR - ABL1 ABL1 Y253H ABL1 F359V"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2513,
            "profileName": "BCR - ABL1",
            "profileTreatmentApproaches": [
                {
                    "id": 4226,
                    "name": "BCR-ABL Inhibitor",
                    "profileName": "BCR - ABL1"
                }
            ]
        },
        {
            "id": 3598,
            "profileName": "BCR - ABL1 ABL1 V299L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5358,
            "profileName": "BCR - ABL1 ABL1 T315I",
            "profileTreatmentApproaches": [
                {
                    "id": 4228,
                    "name": "Rebastinib",
                    "profileName": "BCR - ABL1 ABL1 T315I"
                },
                {
                    "id": 4230,
                    "name": "Ponatinib",
                    "profileName": "BCR - ABL1 ABL1 T315I"
                },
                {
                    "id": 4227,
                    "name": "Danusertib",
                    "profileName": "BCR - ABL1 ABL1 T315I"
                },
                {
                    "id": 4229,
                    "name": "KW-2449",
                    "profileName": "BCR - ABL1 ABL1 T315I"
                }
            ]
        },
        {
            "id": 5391,
            "profileName": "BCR - ABL1 ABL1 E255K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22836,
            "profileName": "BCR - ABL1 ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22837,
            "profileName": "BCR - ABL1 ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22838,
            "profileName": "BCR - ABL1 ABL1 G250E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22839,
            "profileName": "BCR - ABL1 ABL1 M244V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22840,
            "profileName": "BCR - ABL1 ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22841,
            "profileName": "BCR - ABL1 ABL1 E255V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22966,
            "profileName": "BCR - ABL1 ABL1 F359I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22967,
            "profileName": "BCR - ABL1 ABL1 L248V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22968,
            "profileName": "BCR - ABL1 ABL1 Q252H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22969,
            "profileName": "BCR - ABL1 ABL1 Y253H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22970,
            "profileName": "BCR - ABL1 ABL1 E279K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22971,
            "profileName": "BCR - ABL1 ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22972,
            "profileName": "BCR - ABL1 ABL1 H396P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22973,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22975,
            "profileName": "BCR - ABL1 ABL1 E275D ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22977,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 E450G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22978,
            "profileName": "BCR - ABL1 ABL1 T277I ABL1 F359I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22980,
            "profileName": "BCR - ABL1 ABL1 E507G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22982,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 P310L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22983,
            "profileName": "BCR - ABL1 ABL1 P310L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 22987,
            "profileName": "BCR - ABL1 ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23080,
            "profileName": "BCR - ABL1 ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23082,
            "profileName": "BCR - ABL1 ABL1 E355A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23130,
            "profileName": "BCR - ABL1 ABL1 M437I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23131,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23134,
            "profileName": "BCR - ABL1 ABL1 A287V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23135,
            "profileName": "BCR - ABL1 ABL1 Y253H ABL1 A287V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23137,
            "profileName": "BCR - ABL1 ABL1 C475W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23139,
            "profileName": "BCR - ABL1 ABL1 Y253H ABL1 E282D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23141,
            "profileName": "BCR - ABL1 ABL1 K262N ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23143,
            "profileName": "BCR - ABL1 ABL1 M237R ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23145,
            "profileName": "BCR - ABL1 ABL1 F359V ABL1 R362T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23147,
            "profileName": "BCR - ABL1 ABL1 Y456C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23148,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23149,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23150,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23151,
            "profileName": "BCR - ABL1 ABL1 E255K ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23152,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23153,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23154,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23155,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23156,
            "profileName": "BCR - ABL1 ABL1 E279K ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23157,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23161,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 E279V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23163,
            "profileName": "BCR - ABL1 ABL1 E281K ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23165,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 I432M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23167,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 R386M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23169,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23170,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23171,
            "profileName": "BCR - ABL1 ABL1 V379I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23172,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23174,
            "profileName": "BCR - ABL1 ABL1 M237V ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23537,
            "profileName": "BCR - ABL1 ABL1 L384M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23538,
            "profileName": "BCR - ABL1 ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23540,
            "profileName": "BCR - ABL1 ABL1 M388L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23541,
            "profileName": "BCR - ABL1 ABL1 T315L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23542,
            "profileName": "BCR - ABL1 ABL1 Q346L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23543,
            "profileName": "BCR - ABL1 ABL1 S417Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23544,
            "profileName": "BCR - ABL1 ABL1 R362fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23606,
            "profileName": "BCR - ABL1 ABL1 V289F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24816,
            "profileName": "BCR - ABL1 ABL1 T315I RAD51 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24962,
            "profileName": "BCR - ABL1 LYN Y508F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24966,
            "profileName": "BCR - ABL1 GAB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26122,
            "profileName": "BCR - ABL1 ABL1 V379I ABL1 H396P ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26123,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 T315I ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26124,
            "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26125,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 F317L ABL1 F359C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26126,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 Y253H ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26127,
            "profileName": "BCR - ABL1 ABL1 E279K ABL1 E281K ABL1 F317L ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26128,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 R386M ABL1 I432M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26129,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359V ABL1 E450G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26130,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 T277I ABL1 F359I ABL1 E507G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26131,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 G250W ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26132,
            "profileName": "BCR - ABL1 ABL1 K262N ABL1 T315I ABL1 C475W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26133,
            "profileName": "BCR - ABL1 ABL1 M237R ABL1 T315I ABL1 F359V ABL1 R362T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26134,
            "profileName": "BCR - ABL1 ABL1 Y253H ABL1 E282D ABL1 A287V ABL1 Y456C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26231,
            "profileName": "BCR - ABL1 ABL1 E255K ABL1 T315I BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26232,
            "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26233,
            "profileName": "BCR - ABL1 BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26234,
            "profileName": "BCR - ABL1 ABL1 H396R BCL2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26700,
            "profileName": "BCR - ABL1 BCL2 pos MCL1 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26917,
            "profileName": "BCR - ABL1 RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27622,
            "profileName": "BCR - ABL1 ABL1 A337V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27624,
            "profileName": "BCR - ABL1 ABL1 P465S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27628,
            "profileName": "BCR - ABL1 ABL1 V468F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27641,
            "profileName": "BCR - ABL1 ABL1 P223S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27644,
            "profileName": "BCR - ABL1 ABL1 G250H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27645,
            "profileName": "BCR - ABL1 ABL1 I502L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27646,
            "profileName": "BCR - ABL1 ABL1 K294E",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27720,
            "profileName": "BCR - ABL1 ABL1 T315I AURKA pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28357,
            "profileName": "BCR - ABL1 ABL1 amp BCR amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28919,
            "profileName": "BCR - ABL1 IKZF1 R502W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28964,
            "profileName": "BCR - ABL1 ABL1 Y253F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29107,
            "profileName": "BCR - ABL1 ABL1 F317V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29112,
            "profileName": "BCR - ABL1 ABL1 F317I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29116,
            "profileName": "BCR - ABL1 ABL1 F317C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29118,
            "profileName": "BCR - ABL1 ABL1 T315A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31347,
            "profileName": "BCR - ABL1 ABL1 Y440C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33503,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 H396R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33624,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33943,
            "profileName": "BCR - ABL1 ABL1 A344P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33944,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33945,
            "profileName": "BCR - ABL1 ABL1 Y253H ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33946,
            "profileName": "BCR - ABL1 ABL1 E255V ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33947,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33948,
            "profileName": "BCR - ABL1 ABL1 E255V ABL1 V299L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33949,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33950,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33952,
            "profileName": "BCR - ABL1 ABL1 T315M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35405,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 L384M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35406,
            "profileName": "BCR - ABL1 ABL1 E255V ABL1 F317L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35455,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 L384M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35456,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35461,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35462,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35463,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35464,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35465,
            "profileName": "BCR - ABL1 ABL1 F311L ABL1 T315I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35466,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35467,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35468,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 L384M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35469,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35471,
            "profileName": "BCR - ABL1 ABL1 L298V ABL1 V299L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35472,
            "profileName": "BCR - ABL1 ABL1 L298V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35473,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 V299L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35474,
            "profileName": "BCR - ABL1 ABL1 E255V ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35475,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35476,
            "profileName": "BCR - ABL1 ABL1 M244V ABL1 E459K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35477,
            "profileName": "BCR - ABL1 ABL1 G250E ABL1 M351T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35478,
            "profileName": "BCR - ABL1 ABL1 Y253H ABL1 F359V",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}